Selected research
Industry Research
Human Coagulation Factor IX Industry Research Report 2026
Market perspective
The global Human Coagulation Factor IX market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Human Coagulation Factor IX is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Human Coagulation Factor IX is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Human Coagulation Factor IX is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Human Coagulation Factor IX include BPL, CSL, Greencross, Grifols, Kedrion, Octapharma, Baxter, Bayer and Biogen, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Human Coagulation Factor IX market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Human Coagulation Factor IX Market by Company
BPL
CSL
Greencross
Grifols
Kedrion
Octapharma
Baxter
Bayer
Biogen
Hualan Bio
Pfizer
RAAS
Novo Nordisk
Human Coagulation Factor IX Segment by Type
AHGB
AHFB
Others
Human Coagulation Factor IX Segment by Application
Hospital
Personal Clinic
Others
Human Coagulation Factor IX Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Coagulation Factor IX market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Human Coagulation Factor IX and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Coagulation Factor IX.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Human Coagulation Factor IX manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Human Coagulation Factor IX by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Human Coagulation Factor IX in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- AHGB
- AHFB
- Others
Applications
- Hospital
- Personal Clinic
- Others
Companies covered
- BPL
- CSL
- Greencross
- Grifols
- Kedrion
- Octapharma
- Baxter
- Bayer
- Biogen
- Hualan Bio
- Pfizer
- RAAS
- Novo Nordisk
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Human Coagulation Factor IX Market Size (2021-2032)
- 2.2.2 Global Human Coagulation Factor IX Sales (2021-2032)
- 2.2.3 Global Human Coagulation Factor IX Market Average Price (2021-2032)
- 2.3 Human Coagulation Factor IX by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 AHGB
- 2.3.3 AHFB
- 2.3.4 Others
- 2.4 Human Coagulation Factor IX by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Personal Clinic
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Human Coagulation Factor IX Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Human Coagulation Factor IX Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Human Coagulation Factor IX Revenue of Manufacturers (2021-2026)
- 3.4 Global Human Coagulation Factor IX Average Price by Manufacturers (2021-2026)
- 3.5 Global Human Coagulation Factor IX Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Human Coagulation Factor IX, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Human Coagulation Factor IX, Product Type & Application
- 3.8 Global Manufacturers of Human Coagulation Factor IX, Established Date
- 3.9 Global Human Coagulation Factor IX Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 BPL
- 4.1.1 BPL Company Information
- 4.1.2 BPL Business Overview
- 4.1.3 BPL Human Coagulation Factor IX Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 BPL Human Coagulation Factor IX Product Portfolio
- 4.1.5 BPL Recent Developments
- 4.2 CSL
- 4.2.1 CSL Company Information
- 4.2.2 CSL Business Overview
- 4.2.3 CSL Human Coagulation Factor IX Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 CSL Human Coagulation Factor IX Product Portfolio
- 4.2.5 CSL Recent Developments
- 4.3 Greencross
- 4.3.1 Greencross Company Information
- 4.3.2 Greencross Business Overview
- 4.3.3 Greencross Human Coagulation Factor IX Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Greencross Human Coagulation Factor IX Product Portfolio
- 4.3.5 Greencross Recent Developments
- 4.4 Grifols
- 4.4.1 Grifols Company Information
- 4.4.2 Grifols Business Overview
- 4.4.3 Grifols Human Coagulation Factor IX Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Grifols Human Coagulation Factor IX Product Portfolio
- 4.4.5 Grifols Recent Developments
- 4.5 Kedrion
- 4.5.1 Kedrion Company Information
- 4.5.2 Kedrion Business Overview
- 4.5.3 Kedrion Human Coagulation Factor IX Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Kedrion Human Coagulation Factor IX Product Portfolio
- 4.5.5 Kedrion Recent Developments
- 4.6 Octapharma
- 4.6.1 Octapharma Company Information
- 4.6.2 Octapharma Business Overview
- 4.6.3 Octapharma Human Coagulation Factor IX Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Octapharma Human Coagulation Factor IX Product Portfolio
- 4.6.5 Octapharma Recent Developments
- 4.7 Baxter
- 4.7.1 Baxter Company Information
- 4.7.2 Baxter Business Overview
- 4.7.3 Baxter Human Coagulation Factor IX Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Baxter Human Coagulation Factor IX Product Portfolio
- 4.7.5 Baxter Recent Developments
- 4.8 Bayer
- 4.8.1 Bayer Company Information
- 4.8.2 Bayer Business Overview
- 4.8.3 Bayer Human Coagulation Factor IX Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Bayer Human Coagulation Factor IX Product Portfolio
- 4.8.5 Bayer Recent Developments
- 4.9 Biogen
- 4.9.1 Biogen Company Information
- 4.9.2 Biogen Business Overview
- 4.9.3 Biogen Human Coagulation Factor IX Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Biogen Human Coagulation Factor IX Product Portfolio
- 4.9.5 Biogen Recent Developments
- 4.10 Hualan Bio
- 4.10.1 Hualan Bio Company Information
- 4.10.2 Hualan Bio Business Overview
- 4.10.3 Hualan Bio Human Coagulation Factor IX Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Hualan Bio Human Coagulation Factor IX Product Portfolio
- 4.10.5 Hualan Bio Recent Developments
- 4.11 Pfizer
- 4.11.1 Pfizer Company Information
- 4.11.2 Pfizer Business Overview
- 4.11.3 Pfizer Human Coagulation Factor IX Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Pfizer Human Coagulation Factor IX Product Portfolio
- 4.11.5 Pfizer Recent Developments
- 4.12 RAAS
- 4.12.1 RAAS Company Information
- 4.12.2 RAAS Business Overview
- 4.12.3 RAAS Human Coagulation Factor IX Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 RAAS Human Coagulation Factor IX Product Portfolio
- 4.12.5 RAAS Recent Developments
- 4.13 Novo Nordisk
- 4.13.1 Novo Nordisk Company Information
- 4.13.2 Novo Nordisk Business Overview
- 4.13.3 Novo Nordisk Human Coagulation Factor IX Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Novo Nordisk Human Coagulation Factor IX Product Portfolio
- 4.13.5 Novo Nordisk Recent Developments
5 Global Human Coagulation Factor IX Market Scenario by Region
- 5.1 Global Human Coagulation Factor IX Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Human Coagulation Factor IX Sales by Region: 2021-2032
- 5.2.1 Global Human Coagulation Factor IX Sales by Region: 2021-2026
- 5.2.2 Global Human Coagulation Factor IX Sales by Region: 2027-2032
- 5.3 Global Human Coagulation Factor IX Revenue by Region: 2021-2032
- 5.3.1 Global Human Coagulation Factor IX Revenue by Region: 2021-2026
- 5.3.2 Global Human Coagulation Factor IX Revenue by Region: 2027-2032
- 5.4 North America Human Coagulation Factor IX Market Facts & Figures by Country
- 5.4.1 North America Human Coagulation Factor IX Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Human Coagulation Factor IX Sales by Country (2021-2032)
- 5.4.3 North America Human Coagulation Factor IX Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Human Coagulation Factor IX Market Facts & Figures by Country
- 5.5.1 Europe Human Coagulation Factor IX Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Human Coagulation Factor IX Sales by Country (2021-2032)
- 5.5.3 Europe Human Coagulation Factor IX Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Human Coagulation Factor IX Market Facts & Figures by Country
- 5.6.1 Asia Pacific Human Coagulation Factor IX Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Human Coagulation Factor IX Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Human Coagulation Factor IX Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Human Coagulation Factor IX Market Facts & Figures by Country
- 5.7.1 South America Human Coagulation Factor IX Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Human Coagulation Factor IX Sales by Country (2021-2032)
- 5.7.3 South America Human Coagulation Factor IX Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Human Coagulation Factor IX Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Human Coagulation Factor IX Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Human Coagulation Factor IX Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Human Coagulation Factor IX Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Human Coagulation Factor IX Sales by Type (2021-2032)
- 6.1.1 Global Human Coagulation Factor IX Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Human Coagulation Factor IX Sales Market Share by Type (2021-2032)
- 6.2 Global Human Coagulation Factor IX Revenue by Type (2021-2032)
- 6.2.1 Global Human Coagulation Factor IX Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Human Coagulation Factor IX Revenue Market Share by Type (2021-2032)
- 6.3 Global Human Coagulation Factor IX Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Human Coagulation Factor IX Sales by Application (2021-2032)
- 7.1.1 Global Human Coagulation Factor IX Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Human Coagulation Factor IX Sales Market Share by Application (2021-2032)
- 7.2 Global Human Coagulation Factor IX Revenue by Application (2021-2032)
- 7.2.1 Global Human Coagulation Factor IX Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Human Coagulation Factor IX Revenue Market Share by Application (2021-2032)
- 7.3 Global Human Coagulation Factor IX Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Human Coagulation Factor IX Value Chain Analysis
- 8.1.1 Human Coagulation Factor IX Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Human Coagulation Factor IX Production Mode & Process
- 8.2 Human Coagulation Factor IX Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Human Coagulation Factor IX Distributors
- 8.2.3 Human Coagulation Factor IX Customers
9 Global Human Coagulation Factor IX Analyzing Market Dynamics
- 9.1 Human Coagulation Factor IX Industry Trends
- 9.2 Human Coagulation Factor IX Industry Drivers
- 9.3 Human Coagulation Factor IX Industry Opportunities and Challenges
- 9.4 Human Coagulation Factor IX Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst